Pheon, Tridek-One, Optellum
Pheon Therapeutics Raises $68M in Series A Financing
Pheon Therapeutics, a London, UK-based Antibody Drug Conjugate company developing a pipeline of monotherapies for targets and/or with payloads, raised $68M in Series A funding.
The round was led by Brandon Capital, Forbion and Atlas Venture, with participation from Research Corporation Technologies.
The company intends to use the funds to advance its lead ADC program to clinical proof-of-concept and establish a pipeline of novel ADCs.
Led by CEO Bertrand Damour and CSO Leigh Zawel, Pheon Therapeutics is advancing a pipeline of monotherapies for novel targets and/or with novel payloads based on Antibody Drug Conjugates (ADCs). ADCs offer the potential to treat solid tumors and liquid cancers that have not responded to other treatments.
Pheon Therapeutics Raises $68M in Series A Financing - FinSMEs
Pheon Therapeutics, a London, UK-based Antibody Drug Conjugate company developing a pipeline of monotherapies for targets and/or with payloads, raised $68M in Series A funding
French biotech Tridek-One gets €16 million booster to restore the immune balance in patients
Paris-based biotech startup Tridek-One has raised €16 million in funding to speed up its research and development of CD31 agonists to restore the immune balance. The round was led by the Swiss VC Pureos Bioventures with the participation of new investors Bpifrance, through its InnoBio2 fund, and Bioqube Ventures and historical investors AdBio and Advent Life Sciences.
Founded in 2018 by Dr. Giuseppina Caligiuri and Pr. Antonino Nicoletti, the startup develops immune checkpoint agonists to restore the immune balance in patients living with auto-immune diseases.
Going forward, the funds will primarily be used to identify development candidates against auto-immune diseases, to conduct IND-enabling studies and to further build the organisation. The company had earlier raised €3 million in 2019.
French biotech Tridek-One gets €16 million booster to restore the immune balance in patients - Tech.eu
The funds will be used to identify candidates to develop, conduct IND-enabling studies, and further expand in Europe
Optellum Raises $14M in Series A Funding
Optellum, an Oxford, UK-based medtech company that provides an AI platform to diagnose and treat early-stage lung cancer, raised $14M in Series A funding.
The round was led by Mercia, with participation from Intuitive Ventures, Black Opal Ventures, St John’s College in the University of Oxford, IQ Capital, and the family office of Sir Martin & Lady Audrey Wood.
The company intends to use the funds to scale its base, operations, and commercial launches in the UK and USA; accelerate research and development; and expand its platform into personalized therapy decisions by integrating imaging data with molecular data, robotics, and liquid biopsies.
Led by CEO Jason Pesterfield and Founder Tara Bishop, MD, Optellum is the leader in AI-enabled lung cancer diagnosis, attaining FDA clearance, CE-MDR in the EU, and UKCA in the UK for its software platform Virtual Nodule Clinic. This platform can help physicians identify and track at-risk patients, and optimally diagnose the signs of lung cancer early, so treatment can be started sooner for patients with tumors, and invasive procedures such as biopsies on benign lesions can be minimized.
Optellum Raises $14M in Series A Funding
Optellum, an Oxford, UK-based medtech company that provides an AI platform to diagnose and treat early-stage lung cancer, raised $14M in Series A funding
Acurable Raises €11M in Series A Funding Round
Acurable, a London, UK- and Seville, Spain-based medical devices company, raised €11M in Series A funding.
The round was led by Kibo Ventures, with participation from Mundi Ventures, Kindred Capital, and Comprador Holdings.
The company intends to use the funds to build out its distribution network to launch its home sleep testing device AcuPebble SA100 across major European markets and in North America, and invest in its development program for new products based on AcuPebble technology that will help simplify the diagnosis and management of other respiratory and cardiovascular conditions.
Led by CEOs Esther Rodriguez-Villegas and Emilio Sanz, Acurable is a medical devices company that creates wearable medical devices intended to be used by patients themselves at home. Its first product AcuPebble SA100 simplifies obstructive sleep apnoea (OSA) detection and monitoring by enabling fully automated testing of patients at home for the first time. AcuPebble SA100 obtained a CE mark in Europe for the automated diagnosis of obstructive sleep apnoea at home, and received FDA 510(k) clearance in the US.
Acurable Raises €11M in Series A Funding Round - FinSMEs
Acurable, a London, UK- and Seville, Spain-based medical devices company, raised €11M in Series A funding
Charlottesville’s Rivus Pharmaceuticals raises $132M Series B round
Rivus Pharmaceuticals Inc., a clinical-stage biopharmaceutical company based in Charlottesville focused on cardiometabolic health, recently completed a $132 million Series B financing round.
The funding was led by Boston’s RA Capital Management with participation from Boston’s Bain Capital Life Sciences, Switzerland’s BB Biotech AG and existing investors Longitude Capital of Menlo Park, California as well as Medicxi and RxCapital, both based in the U.K.
Rivus said the financing will support further clinical advancement of lead drug candidate HU6, what it bills as a first-in-class controlled metabolic accelerator, or CMA, designed to treat cardiometabolic diseases.
https://www.bizjournals.com/richmond/inno/stories/news/2022/09/28/rivus-pharmaceuticals-funding.htmlPrime Global Acquires earthware
Prime Global Medical Communications acquired earthware, a Newnham, UK-based digital healthcare and technology agency.
The amount of the deal was not disclosed.
As part of Prime Global, earthware will support the company’s pharmaceutical and biotech clients at every step of the healthcare journey.
earthware is a digital healthcare agency that partners with healthcare companies to create digital and technology solutions for healthcare practitioners and patients.
Led by CEO Graeme Peterson, Prime Global offers medical communications, evidence and access, and patient engagement, with people based across the UK, US, Europe, and New Zealand. The company provides pharmaceutical, biotech and healthcare businesses with communications services, including healthcare strategy and consultancy, scientific and medical communications, patient integrated science, RWE and HEOR, and market access.
